Category Archives: Gadolinium

Featured Stories

Zadroga Act Cancer Decision Expected This Week

The federal official tasked with determining what ailments should be covered by the federal Zadroga Act is expected to decide by Saturday if certain cancers will be eligible for compensation. The decision is being eagerly awaited by thousands of first responders who believe they developed cancer due to exposure ...

Read More

Another Metal-on-Metal Hip Replacement Lawsuit Filed in DePuy ASR Hip Implant Litigation

A vital food safety program was saved from budget cuts this week, enabling the country’s largest—although considered by experts to be far too small—produce-safety testing program to continue.

Read More

Older Patients Face Heart Attack Risk Following Surgery

Older Hip Implant, Knee Replacement Patients Face Heart Attack Risk Following Surgery

An emerging report reveals that older hip implant and knee replacement patients face increased heart attack risks following surgery. The risk for acute myocardial infarction (AMI) was seen in the first two weeks after these surgical procedures.

Read More

Bisphosphonate Study Confirms Atypical Thigh Fracture Risk

New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a ...

Read More

Smith & Nephew Recalls Metal-on-Metal Hip Implant Component

Medical device maker, Smith & Nephew, just issued a recall for a metal-on-metal hip implant component, a part of one of its all-metal hip replacement systems.

Read More

Canadian Study Finds Actos Raises Bladder Cancer Risk by 22 Percent

Yet another study is confirming the association between the diabetes drug, Actos, and bladder cancer. This latest research, published today in the Canadian Medical Association Journal, found that taking Actos raised the risk of bladder cancer among diabetics by about one-fifth.

Read More

Actos Whistleblower Lawsuit Questions Avandia Researcher's Financial Ties to Takeda

A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and the maker of Actos “should be considered when analyzing Actos’s ...

Read More

E-cigarettes Could Increase Risk of Lung Infections

E-cigarettes Could Increase Risk of Lung Infections

New research suggests the liquid used in electronic cigarettes could increase the risk of viral lung infections, regardless of whether it contains nicotine.

Read More

Medtronic Settles Charges Over Kickbacks To Doctors

Medical device giant, Medtronic Inc., is settling charges over kickbacks to doctors. The firms just agreed to pay $23.5 million to settle claims it paid physicians kickbacks in exchange for their use of its pacemakers and defibrillators, according to a U.S. Justice Department announcement yesterday. The company was accused of seeking ...

Read More

Fracking Should be Kept 600m From Aquifers, Study Says

New research on the safety of hydraulic fracturing (fracking) suggests new wells should not be dug within 600 meters of a water aquifer because underground fractures can extend about that far from a dug well. According to a report from UK’s The Guardian newspaper, researchers and geologists at Durham University have ...

Read More

FDA Advisors Meet on Gadolinium Dyes; Find Omniscan, OptiMark and Magnevist are Most Dangerous

A panel of medical experts has found that several gadolinium contrast dyes – < "http://www.yourlawyer.com/articles/read/17387">OptiMark, Omniscan and Magnevist – appear to carry more risk of nephrogenic systemic fibrosis (NSF) than others currently on the market. The advisory panel met yesterday … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Restrict Some Gadolinium Contrast Dyes, FDA Panel Says

The use of some gadolinium contrast dyes should be restricted because of their association with nephrogenic systemic fibrosis (NSF), according to a recommendation just made by a Food & Drug Administration (FDA) advisory panel. Reuters is reporting that the panel … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Gadolinium Contrast Dyes Face FDA Advisory Panel Review Next Week

U.S. health regulators are set to review gadolinium contrast dyes this month. The Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will meet on December 8 to review data … Continue reading

Posted in Gadolinium, Pharmaceuticals |

NSF Lawsuit Claims Hospital Negligent For Using Gadolinium Contrast Dyes

St. Luke’s Hospital in Chesterfield, Mo. faces a lawsuit filed by a victim of < "http://www.yourlawyer.com/topics/overview/nsf">nephrogenic systemic fibrosis (NSF). The plaintiff was administered a gadolinium based contrast dye at St. Luke’s several times starting in 2005, and was diagnosed with … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Dialysis, Kidney Transplant Patients Face Higher Risk of NSF from Gadolinium Agents

A study of patients exposed to gadolinium contrast dyes at the Mayo Clinic has revealed that hemodialysis patients had a 77-fold higher risk of developing nephrogenic systemic fibrosis (NSF), while kidney transplant patients had a 69-fold higher risk of the … Continue reading

Posted in Gadolinium, Pharmaceuticals |

OptiMARK Gadolinium Contrast Agent Label Changed Over NSF Risk

The maker of OptiMARK gadolinium contrast agent is modifying the product’s label to contraindicate its use in patients with severe kidney impairment because of its association with nephrogenic systemic fibrosis (NSF). Mallinckrodt Inc., a Covidien company, has submitted this label … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Magnevist, Omniscan and OptiMARK Have Highest Risk of NSF, FDA Says

Three gadolinium contrast dyes – Bayer Healthcare’s Magnevist, GE Healthcare’s Omniscan, and Covidien ‘s OptiMARK -carry a higher risk of < "http://www.yourlawyer.com/topics/overview/nsf">nephrogenic systemic fibrosis (NSF) than other agents on the market, according to the U.S. Food & Drug Administration (FDA). … Continue reading

Posted in Gadolinium, Pharmaceuticals |

FDA Decision to Treat Omniscan, Other Gadolinium Contrast Dyes Equally Questioned

A ProPublica investigation has found that a disproportionate number of Nephrogenic Systemic Fibrosis (NSF) cases have been associated with the use of General Electric’s (GE) < "http://www.yourlawyer.com/topics/overview/omniscan_gadolinium">Omniscan gadolinium contrast dye. Yet, according to the investigation, published in Business Week, the … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Bayer Settles Some Magnevist Gadolinium Contrast Dye Lawsuits

Bayer AG has settled some lawsuits involving its < "http://www.yourlawyer.com/topics/overview/gadolinium">gadolinium contrast dye, Magnevist. Plaintiffs in the lawsuits claimed that Magnevist had caused Nephrogenic Systemic Fibrosis (NSF), a potentially fatal condition that develops in people with pre-existing kidney disease. Gadolinium contrast … Continue reading

Posted in Gadolinium |

Study Suggests "Potent" Link Between NSF, Gadolinium Contrast Dyes

Another study has found a strong link between the use of gadolinium contrast dyes and the development of Nephrogenic Systemic Fibrosis (NSF). According to researchers at the University of Pennsylvania in Philadelphia, patients with advanced chronic kidney disease were 27 … Continue reading

Posted in Gadolinium |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.